Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry

  1. Corinna Popp
  2. Philipp Schramm
  3. Ralf Wagner
  4. David Peterhoff
  5. Christopher Battle
  6. Christian Kleusch
  7. Maximilian G. Plach

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

Vaccines are on the front line-of-defense against infectious diseases, ranging from threats we are familiar with, including polio, tuberculosis, or HIV, to novel and emerging threats such as SARS-CoV-2. Successful development of new protein-based vaccines requires sophisticated and efficient development of storage and formulation conditions. Here we demonstrate the combined power of 2bind’s sophisticated buffer matrix FORMOscreen ® and NanoTemper Technologies’ novel Prometheus Panta high-throughput Dynamic Light Scattering/Nano Differential Scanning Fluorimetry instrument. We show that this combination can comprehensively improve critical biophysical parameters for the HIV-1 vaccine BG505-SOSIP and find the optimal formulation condition with unmatched efficiency.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.11.30.403873: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This showcases one limitation of such a continuous variation binding assay: The hydrodynamic radii of the involved species must not deviate from each other with a factor >2 (or in other words, the molecular weights of the involved species should not be more different than 5-fold) [9]. A control with a non-related antibody (The NIST monoclonal antibody (NISTmAb) reference material, RM 8671) [12] did not show signs of an interaction and the average hydrodynamic radius continuously changed from the BG505-SOSIP radius to that of the antibody (Figure 4C).

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2020.11.30.403873v1 on bioRxiv